How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration.

Cancer screening Pilot studies Prostate cancer

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Jul 2023
Historique:
accepted: 02 05 2023
medline: 13 7 2023
pubmed: 13 7 2023
entrez: 13 7 2023
Statut: epublish

Résumé

An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.

Identifiants

pubmed: 37441346
doi: 10.1016/j.euros.2023.05.011
pii: S2666-1683(23)00252-5
pmc: PMC10334243
doi:

Types de publication

Journal Article

Langues

eng

Pagination

106-108

Informations de copyright

© 2023 The Author(s).

Références

Eur Urol. 2021 Dec;80(6):703-711
pubmed: 34407909
Eur Urol Focus. 2022 Nov;8(6):1568-1574
pubmed: 35811285
Nat Rev Urol. 2022 Sep;19(9):562-572
pubmed: 35974245
Eur Urol. 2014 Feb;65(2):329-36
pubmed: 23954085
N Engl J Med. 2023 Apr 27;388(17):1547-1558
pubmed: 36912538
Eur Urol. 2021 Mar;79(3):327-329
pubmed: 33384200
N Engl J Med. 2021 Sep 2;385(10):908-920
pubmed: 34237810
J Cancer Policy. 2018 Dec;18:40-51
pubmed: 30510896

Auteurs

Ondřej Májek (O)

National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Marek Babjuk (M)

Department of Urology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czechia.

Monique J Roobol (MJ)

Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands.

Ola Bratt (O)

Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Hendrik Van Poppel (H)

European Association of Urology Policy Office, Arnhem, The Netherlands.
Department of Urology, KU Leuven, Leuven, Belgium.

Roman Zachoval (R)

Department of Urology, 3rd Faculty of Medicine of Charles University and Faculty Thomayer Hospital, Prague, Czechia.

Jiří Ferda (J)

Department of Imaging Methods, Medical Faculty Pilsen, Charles University, University Hospital Pilsen, Pilsen, Czechia.

Marcela Koudelková (M)

National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Ondřej Ngo (O)

National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Jakub Gregor (J)

National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Sarah Collen (S)

European Association of Urology Policy Office, Arnhem, The Netherlands.

Karel Hejduk (K)

National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Ladislav Dušek (L)

National Screening Centre, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Vlastimil Válek (V)

Faculty of Medicine, Masaryk University, Brno, Czechia.
Ministry of Health of the Czech Republic, Prague, Czechia.

Classifications MeSH